Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six...
HKG: 3692
Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...
Hansoh Pharmaceutical Partners with Regeneron for HS-20094 Global Rights
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with Regeneron Pharmaceuticals...
Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...
Hansoh’s HS-20093 ADC Earns BTD for Advanced NSCLC from China’s NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that China’s National Medical Products...
Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...
Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...
Amgen’s Uplizna Approved by FDA for IgG4-Related Disease
US biotech giant Amgen (NASDAQ: AMGN) announced that it has received marketing approval from the...
Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...
Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...
Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...
Hansoh Pharmaceutical’s HS-10561 Receives NMPA Clearance for Chronic Spontaneous Urticaria
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received clinical trial...
Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...
Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
EMA Grants PRIME Designation to Hansoh Pharmaceutical’s HS-20093 in Collaboration with GSK
The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a...
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...
Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...